Stem cell therapy for chronic diffuse liver lesions: main symptoms and causes

Gastroenterology Review, 2025

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.5114/pg.2025.154589
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction: Chronic liver damage is one of the most important and complex problems in modern gastroenterology. The relevance of studying chronic hepatitis of various aetiologies is associated with its high socio-economic and medical significance due to the steady progressive course, with the development of fibrosis, and then cirrhosis of the liver. Aim: The purpose of this study was to search for and analyse new biotechnological methods for the treatment of diffuse liver diseases to improve patient survival, since the main contingent of patients is typically the able-bodied, socially active part of the population. Material and methods: To achieve this goal, general theoretical methods of scientific knowledge were used, such as analysis, generalization, questioning, and systematization. Results: The article presents a meta-analysis of the results of studies conducted in the field of cellular technologies by leading scientists in the field of the treatment of liver diseases. The issues of transdifferentiation, the mechanisms of action of stem cells in hepatology, as well as the possible risks of this therapy (pro-oncogenic effect, increased fibrosis), are covered. Conclusions: Cell therapy in embryonic, mononuclear, and mesenchymal stromal cells is the most advanced area of modern biotechnology and medicine. Its therapeutic application in chronic liver diseases is base on the possibility of regulating disturbed intercellular interactions in the liver, influencing the mechanisms of cell death (necrosis, apoptosis) and fibrogenesis, which makes this method the most relevant and promising in hepatology.